Cybin's HLP003 Phase 3 Trial Nears Full Enrollment, Surpassing 86% for MDD Treatment
Summary
Cybin Inc. announced that its HLP003 Phase 3 clinical trial for Major Depressive Disorder has surpassed 86% enrollment, progressing as planned towards potential commercialization.
Key Events
-
Phase 3 Enrollment Update
The APPROACH Phase 3 clinical trial for HLP003, targeting Major Depressive Disorder (MDD), has surpassed 86% enrollment and is progressing as planned.
-
Breakthrough Therapy Designation
HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development and review.
-
Strong Phase 2 Efficacy Data
Previous Phase 2 data for HLP003 demonstrated long-term efficacy, with 100% response and 71% remission rates at 12 months after two doses.
Analysis
For a clinical-stage pharmaceutical company, reaching over 86% enrollment in a pivotal Phase 3 trial with Breakthrough Therapy Designation is a critical de-risking event. This progress moves HLP003 significantly closer to a potential data readout and regulatory submission, which are key milestones for the company's valuation and future. This follows a partnership announced on April 28, 2026, aimed at boosting recruitment for this trial, indicating successful execution.
At the time of this filing, HELP was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $3.76 to $9.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.